Abstract
Aims: To evaluate in a real practice setting effectiveness, safety and adherence to weekly subcutaneous semaglutide for weight
reduction, along with diet and lifestyle modifications in obese/overweighted patients attending an Obesity Unit.
Materials and Methods: In a retrospective study, 367 patients (mean age 50.25 years, 78.36% female, mean baseline body
mass index 32.39 kg/m2) were followed for 10.7 months (median) after initiation of semaglutide. Up to 24.25% of patients were
previously on GLP-1 analogue therapy (mostly liraglutide) and 36.26% used background oral medication for weight loss.
Results: At final office visit patients averaged a weight loss of
7.97±3.42 kg (9.13±3.86% baseline body weight) and 88.07%
and 30.27% of patients had achieved a≥5% and ≥10% weight loss,
respectively, as compared to baseline body weight. Up to 61.19%
and 33.46% of patients maintained 0.5 and 1.0 mg dose, respectively and
86.18% of patients persisted on sc semaglutide by last
office visit. Nausea and abdominal pain were reported by 12.53% of
patients with no severe adverse events. Background antiobesity
medication did not affect weight loss and patients on previous GLP-1
analogue therapy lost 1.43 kg less than naïve patients
(p<0.001).
Conclusions: Out-of-label weekly administration of sc semaglutide
0.5 to 1.0 mg resulted in a significant, safe and affordable
weight loss in a pragmatic setting without reimbursement of treatment
cost. Magnitude of weight loss and safety profile was in line
with preliminary data from a phase 2 trial, although this will need to
be confirmed by an ongoing phase 3 development programme.
Read more About This article: https://lupinepublishers.com/diabetes-obesity-journal/fulltext/effectiveness-safety-and-therapeutic-adherence-of-weekly-subcutaneous-semaglutide-for-weight-management-in-real-practice-an-observational-study.ID.000161.php
Read more Lupine Publishers Google Scholar Articles : https://scholar.google.com/citations?view_op=view_citation&hl=en&user=nqY8h-kAAAAJ&citation_for_view=nqY8h-kAAAAJ:qUcmZB5y_30C
No comments:
Post a Comment